1. Home
  2. Universitat de Barcelona
  3. Genètica, Microbiologia i Estadística
  4. View Item

Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain

Author

Cantarero, David

Ocaña, Daniel

Onieva-García, María Ángeles

Rodríguez-García, Juan

Gálvez, Paulina

Méndez, Cristina

Crespo Palomo, Carlos

López-Ibáñez de Aldecoa, Alejandra

Publication date

2025-02-19T12:34:37Z

2025-02-19T12:34:37Z

2023-08-14

2025-02-19T12:34:37Z

Share

Abstract

A cost-utility analysis was conducted to assess the efficiency of implementing a PCV20 vaccination strategy in the Spanish adult population older than 60 years, for the prevention of non-bacteremic pneumococcal pneumonia (NBP) and invasive pneumococcal disease (IPD).

Document Type

Article

Accepted version

Language

English

Subjects and keywords

Vacuna antipneumocòccica; Anàlisi cost-benefici; Pneumococcal vaccine; Cost effectiveness

Publisher

Elsevier B.V.

Related items

Reproducció del document publicat a: https://doi.org/10.1016/j.vaccine.2023.07.016

Vaccine, 2023, vol. 41, num.36, p. 5342-5349

https://doi.org/10.1016/j.vaccine.2023.07.016

Recommended citation

This citation was generated automatically.

Export

DIDL MARC MARC_CCUC METS OAI_DC ORE QDC RDF

Rights

cc-by-nc-nd (c) Elsevier B.V., 2023

http://creativecommons.org/licenses/by-nc-nd/3.0/es/

This item appears in the following Collection(s)

Genètica, Microbiologia i Estadística [2019]

ISGlobal - Institut de Salut Global de Barcelona [60808]